| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Shashank P Behere | |
| Steven N Weindling | |||
| P2860 | cites work | Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death | Q24300356 |
| Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human | Q24307681 | ||
| Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans | Q24608179 | ||
| Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death | Q24674590 | ||
| Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology | Q28088530 | ||
| Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia | Q28201561 | ||
| A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel | Q28204838 | ||
| The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading [...] | Q28265202 | ||
| Catecholaminergic polymorphic ventricular tachycardia | Q28287523 | ||
| CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. | Q30557177 | ||
| Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. | Q33147854 | ||
| Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia | Q33155477 | ||
| Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia | Q33157356 | ||
| Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia | Q33159716 | ||
| Syncope during exercise: just another benign vasovagal event? | Q33160228 | ||
| Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments | Q33160416 | ||
| Clinical characteristics and mutational analysis of the RyR2 gene in seven Czech families with catecholaminergic polymorphic ventricular tachycardia | Q33161218 | ||
| Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives | Q33161522 | ||
| Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome | Q33161560 | ||
| Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. | Q33162208 | ||
| Arrhythmogenic channelopathy syndromes presenting as refractory epilepsy | Q33163040 | ||
| Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia | Q33163165 | ||
| Exon 3 deletion of RYR2 encoding cardiac ryanodine receptor is associated with left ventricular non-compaction | Q33163701 | ||
| Predicting utility of exercise tests based on history/holter in patients with premature ventricular contractions | Q33164632 | ||
| Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry | Q33165339 | ||
| Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. | Q33165777 | ||
| Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients | Q33173888 | ||
| Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice | Q33919047 | ||
| The role of mutant protein level in autosomal recessive catecholamine dependent polymorphic ventricular tachycardia (CPVT2). | Q33919062 | ||
| Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice | Q33940815 | ||
| Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia | Q34629553 | ||
| Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. | Q35242390 | ||
| Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia | Q36037969 | ||
| Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. | Q36399631 | ||
| Cardiac ion channelopathies and the sudden infant death syndrome | Q36486478 | ||
| Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients. | Q36696236 | ||
| Bidirectional tachycardia in a child. A study using His bundle electrography | Q36822217 | ||
| Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation | Q37294805 | ||
| Videoscopic left cardiac sympathetic denervation for patients with recurrent ventricular fibrillation/malignant ventricular arrhythmia syndromes besides congenital long-QT syndrome | Q37550754 | ||
| Catecholaminergic polymorphic ventricular tachycardia: from bench to bedside | Q38079785 | ||
| Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate | Q38106029 | ||
| Left thoracoscopic sympathectomy for cardiac denervation in patients with life-threatening ventricular arrhythmias | Q38165567 | ||
| Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: risk factor and potential therapeutic target? | Q38238961 | ||
| Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia | Q41268618 | ||
| The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. | Q41484309 | ||
| Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. | Q42215203 | ||
| T-cell-mediated inflammatory activity in the stellate ganglia of patients with ion-channel disease and severe ventricular arrhythmias. | Q42236699 | ||
| Genetic background of catecholaminergic polymorphic ventricular tachycardia in Japan | Q44293793 | ||
| Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations | Q45273441 | ||
| Gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia | Q45866288 | ||
| Flecainide in CASQ2-mediated catecholaminergic polymorphic ventricular tachycardia: the gift that keeps on giving | Q47673840 | ||
| Complex atrial arrhythmias as first manifestation of catecholaminergic polymorphic ventricular tachycardia: an unusual course in a patient with a new mutation in ryanodine receptor type 2 gene | Q47680651 | ||
| The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT. | Q47723591 | ||
| New data on catecholaminergic polymorphic ventricular tachycardia in Japan: from the bench to the bedside. | Q50959364 | ||
| ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiolo | Q51137889 | ||
| Catecholaminergic polymorphic ventricular tachycardia and midventricular Takotsubo cardiomyopathy: a novel association? | Q51254048 | ||
| A novel early onset lethal form of catecholaminergic polymorphic ventricular tachycardia maps to chromosome 7p14-p22 | Q55843608 | ||
| Effects of Individualized Exercise Training in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 | Q58867587 | ||
| Delay to diagnosis amongst patients with catecholaminergic polymorphic ventricular tachycardia | Q61632866 | ||
| Successful catheter ablation of bidirectional ventricular premature contractions triggering ventricular fibrillation in catecholaminergic polymorphic ventricular tachycardia with RyR2 mutation | Q83447670 | ||
| Are there juvenile and adult types in patients with catecholaminergic polymorphic ventricular tachycardia? | Q83455336 | ||
| Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia | Q83821934 | ||
| Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia | Q84064369 | ||
| Phenotype variability in patients carrying KCNJ2 mutations | Q84141829 | ||
| Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia | Q85005791 | ||
| Catecholaminergic polymorphic ventricular tachycardia (CPVT) initially diagnosed as idiopathic ventricular fibrillation: the importance of thorough diagnostic work-up and follow-up | Q86129816 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ventricular tachycardia | Q56002 |
| tachycardia | Q209583 | ||
| catecholaminergic polymorphic ventricular tachycardia | Q1649897 | ||
| P304 | page(s) | 137-46 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Annals of Pediatric Cardiology | Q4767857 |
| P1476 | title | Catecholaminergic polymorphic ventricular tachycardia: An exciting new era | |
| P478 | volume | 9 |
| Q90447356 | Catecholaminergic polymorphic ventricular tachycardia due to de novo RyR2 mutation: recreational cycling as a trigger of lethal arrhythmias |
| Q48230851 | Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. |
| Q89961129 | Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia |
Search more.